Despite the darkness and the rain University College School held a late afternoon run to raise funds for their chosen charity Secondary1st. The muddy conditions failed to deter the runners and the wonderful upbeat atmosphere added to the overall fun for everyone. The School event received a remarkable level of support and raised an amazing…
Details
Laurence finished walking the length of the Camino de Santiago with memories of the many miles she had covered and mental images of mountains and motorways, cats and cows and wonderful scenery. She was helped along the way by the yellow arrows marking the route which were first painted by a local priest and scholar.
A young, healthy, active teacher in Glasgow found a lump in her breast but was told at first that it was a benign cyst, so she ran the Boston marathon and got engaged. Some months later after the lump had grown bigger she was diagnosed with triple negative breast cancer. She then went through chemotherapy,…
Details
Secondary1st is delighted to announce that, thanks to our wonderful donors and fundraisers, we have made a grant to fund a post-doctoral researcher in a new project run by Professor Seth Coffelt at the Beatson Institute for Cancer Research at the University of Glasgow. This new project follows previous research funded by Secondary1st which identified gamma…
Details
First it was the zipwire, then it was a cycle ride from Land’s End to John O’Groats and now Nolan with support from his family and friends has raised a total of more than £23,000 in memory of Nic for Secondary1st. But that isn’t enough for him as he is already planning another challenge for…
Details
NICE now recommends capivasertib, also known as truqap and made by Astra Zeneca, with fulvestrant for those with HR positive HER2 negative metastatic breast cancer with certain genetic mutations after endocrine or hormone therapy. Capivasertib tablets are to be taken twice a day to block the action of an abnormal protein that tells cancer cells…
Details
The NHS in England has started offering liquid biopsies to some women with breast cancer that has mutated. These circulating tumour DNA (ctDNA) blood tests will show whether women with ER-positive HER2 negative secondary breast cancer have developed the ESR1 mutation which can sometimes occur after long-term treatment with hormone therapy. ER-positive cancer cells are…
Details
Olaparib (Lynparza) has now been approved by NICE as a second-line treatment of HER2-negative locally advanced or metastatic breast cancer in adults with mutated BRCA1 or BRCA2 genes who have had chemotherapy. Olaparib is a PARP inhibitor; PAPR is a protein which helps cancer cells repair themselves and Olaparib stops this repair process in these…
Details
In 2024 thanks to donors and fundraisers Secondary1st funded the first year of a research project led by Professor Simak Ali at Imperial College London investigating how changes in the ER gene contribute to hormone therapy resistance. About 44,000 people are diagnose with ER (oestrogen receptor) positive breast cancer each year in the UK and…
Details
The wonderful Alina, a specialist breast cancer nurse, arranged a pre-Christmas afternoon of music and song by courtesy of the Wellington Hospital. Three brilliant stars of musical theatre sang favourite songs from popular shows with keyboard accompaniment and helped to raise more than £600 for Secondary1st.
Next month the NHS will start to use a new ”ping and book” service to remind women via their phones that they are due or even overdue an appointment for breast cancer screening which they can then book through the NHS app. Data for 2022-23 has shown that 35.4% of women did not accept the…
Details
Laurence has just walked over 350km to reach the halfway point of the Camino de Santiago in north-western Spain and has raised over £1000 for Secondary First …. and she is not finished yet! In May she will be returning to the Camino to complete the last 400 km, reach Santiago de Compostela and raise…
Details